Ground-breaking, patented mesh technologies.
The Benignancy Group is at the forefront of research and development to introduce novel therapies in Otolaryngology, Head and Neck Surgery through an individualised, patient-centric model. Our ground-breaking, patented mesh technologies improve patient outcomes and quality of life while our state-of-the-art manufacturing facilities ensure that these meshes are expertly manufactured in Australia, by Australians.
Our Technology
Our technology is something we’re extremely proud of, we like to call it the Mesh Effect.
Myringomesh, one of our suite of novel products that helps heal perforated eardrums, has forged a ground-breaking resarch collaboration with the University of New South Wales (UNSW). Read more here.
What are we trying to achieve here?
Head and neck cancer (HNC) is the 7th most common cancer in Australia and globally, with causes and burdens that are dynamic, significant, and growing.
We are a socially-minded biotech committed to improving health outcomes for all. From our degradable Onco-Mesh bound with cancer-killing agents for direct and controlled cancer treatment to our dissolving Myringomesh that heals perforated ear drums, we prioritise an individualised, patient-centric approach.
Our Mission
We believe biotechnology companies have a responsibility to improve quality of life for all so we take pride in our strong social focus.
Find out more about what we do and why we do it.